Abiopharma

🔍 Linetsky David (Executive)

Company: Phreesia, Inc. (PHR)

Report Date: 2026-01-15

Detailed Transactions and Holdings:

• Sold 1,743 shares of Common Stock at $16.3795 per share (Direct)
  Date: 2026-01-15 | Code: S | equity_swap_involved: 0 | shares_owned_after: 229,980.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 6,038 shares of Common Stock at $16.3568 per share (Direct)
  Date: 2026-01-16 | Code: S | equity_swap_involved: 0 | shares_owned_after: 223,942.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-15 | Code: H | nature_of_ownership: By Spouse | shares_owned_after: 9,789.00

Footnotes:

• F1: These shares were disposed of in non-discretionary transactions pursuant to the Issuer's mandatory sell-to-cover policy to cover the holder's tax withholding obligations in connection with the settlement of an award of restricted stock units.
• F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.185 to $16.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.14 to $16.495 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.